TMO vs A — Key Metrics
| Metric | TMO (THERMO FISHER SCIENTIFIC INC) | A (AGILENT TECHNOLOGIES INC) |
|---|---|---|
| Price | 692.74 | 177.33 |
| Market Cap | 256.67 Billion | 49.99 Billion |
| P/E (TTM) | 36.48 | 34.77 |
| P/B (Quarterly) | 4.716 | 5.741 |
| P/S (TTM) | 5.42 | 6.78 |
| Net Profit Margin (TTM) | 14.9 | 19.5 |
| Gross Margin (TTM) | 41.1 | 53.8 |
| ROE (TTM) | 13.3 | 20.5 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Underperform
Underperform
Recommendation Summary
Stock TMO is projected to greatly underperform the market, stock A is projected to underperform the market. Upfront Recommendation: A.
Financial Metrics
| TMO | Metrics | A |
|---|---|---|
| $692.74 | Price | $177.33 |
| — | Market Capitalization | — |
| 36.48 | Price to Earnings Ratio | 34.77 |
| 5.42 | Price to Sales | 6.78 |
| 33.61 | Price to FCF Ratio | 39.46 |
| 13.19 | Price to Gross Profit | 12.6 |
| 182.81 | Price to R&D | 103.08 |
| 10.02 | Price to Current Assets | 10.65 |
TMO vs A at a glance
Thermo Fisher Scientific INC (TMO) and Agilent Technologies INC (A) are both Diagnostics & Research companies in the Healthcare sector. TMO is the larger, at $256.7 billion in market value against $50.0 billion for A, about 5.1 times the size.
On trailing-twelve-month figures, TMO trades at 36.5 times trailing earnings and A at 34.8; net profit margins are 14.9% and 19.5%.
The Upfront Investment model currently rates TMO Greatly Underperform and A Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.